Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q4 2025
Kiniksa Pharmaceuticals International (KNSA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $202M for the fourth quarter 2025 (Q4 2025), +65% from a year earlier and +12% from the quarter before. Operating margin was 9.8%, net earnings $14.2M (7.0% of revenue).
Kiniksa Pharmaceuticals International, Q4 2025: revenue $202M (+65% year over year), operating margin 9.8%, net earnings $14.2M, operating cash flow $53.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $202M | +12% | +65% |
| Operating profit | $19.8M | -18% | — |
| Net earnings | $14.2M | -23% | — |
| Operating cash flow | $53.9M | +60% | +187% |
| Free cash flow | $53.3M | +61% | +187% |
What changed
Revenue was $202.1M in Q4 2025, up 65% year over year and up 12% from the previous quarter.
Operating profit was $19.8M, a 9.8% margin (up 25.5 points year over year). Total costs grew 29% against revenue growth of 65%. The fastest-growing cost line was Other operating costs (+45%). Net earnings were $14.2M. The effective tax rate was 39.0%.
Operating cash flow was $53.9M (up 187% year over year), 380% of net earnings. Non-cash charges added back $467K of depreciation and amortization and $10.2M of share-based compensation. Working capital and other items added $29.0M. Capital expenditures of $633K left free cash flow of $53.3M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the fourth quarter 2025?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $202M for the fourth quarter 2025 (Q4 2025), +65% from a year earlier and +12% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the fourth quarter 2025?
Operating profit was $19.8M (9.8% of revenue) and net earnings $14.2M.
Source: Kiniksa Pharmaceuticals International 10-K on SEC EDGAR.